The clinical role of somatostatin analogues as antineoplastic agents: Much ado about nothing?

Annals of Oncology

Volumn 13, Issue 5, 2002, Pages 653-668

  Hejna, M ^a   Schmidinger, M ^a   Raderer, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anticancer therapy; Clinical trials; Somatostatin analogues

Indexed keywords

ANGIOPEPTIN; ANTINEOPLASTIC AGENT; GLUCOSE; HORMONE DERIVATIVE; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TAMOXIFEN; VAPREOTIDE; CYCLOPEPTIDE; DRUG DERIVATIVE; SOMATOSTATIN;

ANTINEOPLASTIC ACTIVITY; BIOCHEMISTRY; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL DISEASE; HEALTH STATUS; HISTOLOGY; HUMAN; HYPERGLYCEMIA; HYPOTHYROIDISM; LIVER CELL CARCINOMA; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDLINE; METHODOLOGY; NAUSEA AND VOMITING; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PUBLICATION; REVIEW; SYMPTOM; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; CONTROLLED CLINICAL TRIAL; FEMALE; MALE; MORTALITY; NEOPLASM; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMAN; MALE; NEOPLASMS; OCTREOTIDE; PEPTIDES, CYCLIC; RANDOMIZED CONTROLLED TRIALS; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; HUMANS;

EID: 0035985284     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf142     Document Type: Review

References (125)

1. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone
2. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro
3. Endogenous somatostatin and the gut
4. Somatostatin
5. Secretion of somatostatin and its physiologic function
6. Somatostatin and octreotide: Literature review and description of therapeutic activity in pancreatic neoplasia
7. Somatostatin (first of two parts)
8. Somatostatin (second of two parts)
9. Effect of exogenous somatostatin infusion on gastrointestinal blood flow and hormones in the conscious dog
10. Circulatory effects of somatostatin in anesthetized man
11. Mechanisms of antineoplastic action of somatostatin analogs
12. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands
13. Effects of somatostatin analogue SMS 201-995 in normal man
14. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
15. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumors, efficacy of oral administration, and possible use in nontumoral inappropriate TSH hypersecretion
16. Oncological applications of somatostatin analogues
17. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin
18. SMS 201-995 induces a continous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years
19. Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995
20. Successful treatment of pancreatic ascites with somatostatin analog (SMS 201-995)
21. Pancreatic cholera syndrome: Effect of a synthetic somatostatin analog on intestinal water and ion transport
22. Long-acting somatostatin analog inhibits calcium and secretin stimulated gastrin release in the Zollinger-Ellison syndrome
23. Observations on the effect of a somatostatin analog in the Zollinger-Ellison syndrome: Implications for the treatment of apudomas
24. Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome
25. Somatostatin analogue (SMS 201-995) in patients with gastrinomas
26. Malignant insulinoma: Effects of a somatostatin analog (compound 201-995) on serum glucose, growth, and gastro-entero-pancreatic hormones
27. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumor growth
28. Somatostatin and analogues in the treatment of VIPoma
29. Somatostatin analogue SMS 201-995 long term therapy for VIPoma
30. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases
31. Regression of metastatic VIPoma with somatostatin analogue SMS 201-995
32. Treatment of inoperable glucagonoma with the long acting somatostatin analogue SMS 201-995
33. Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome
34. Use of a somatostatin analogue in association with surgery and hepatic arterial embolisation in the treatment of the carcinoid syndrome
35. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue
36. Rat mammary carcinoma regressions during suppression of serum growth hormone and prolactin
37. Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells
38. Inhibition of growth of human breast carcinomas in vivo by somatostatin analogue, SMS 201-995, treatment of nude mouse xenografts
39. Antiproliferative effects of somatostatin and the somatostatin analog SMS 201-995 on three human breast cancer cell lines
40. Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers
41. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer
42. Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH
43. Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin
44. Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer
45. A long acting somatostatin analog (SRIF) (SMS 201-995) and proglumide (PGL) inhibit the trophic and gastrin receptor (GR) regulatory effects of pentagastrin (PG) on mouse colon cancer (MC-26) cells in vivo
46. Somatostatin and α-difluoromethylornithine (DFMO) have additive inhibitory effects on growth of human colon carcinoma in vivo
47. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones
48. Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995
49. Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line
50. Somatostatin inhibits growth of human small cell lung carcinoma in vivo
51. In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by y somatostatin analogue
52. Potential role of somatostatin analogues in the treatment of cancer
53. Somatostatin analogue phase I trials in neuroendocrine neoplasms
54. Clinical efficacy in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology Group
55. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastrointestinal tumors
56. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects
57. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms
58. Evaluation of a somatostatin analogue in the treatment of lymphoproliferative disorders: Results of a phase II North Central Cancer Treatment Group Trial
59. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: Clinical activity and effects on insulin-like growth factor-I (IGF-I) levels
60. Feasibility, endocrine and anti-tumor effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: A randomized study with long-term follow-up
61. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer
62. SMS 201-995 in the treatment of refractory prostatic cancer
63. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer
64. A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer
65. Experimental and clinical studies with somatostatin analogue octreotide in small-cell lung cancer
66. Phase I study of the somatostatin analogue somatuline in refractory small-cell lung cancer
67. Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer
68. A randomized trial of octreotide versus best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy
69. A phase III evaluation of somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma
70. Octreotide reduces the kinetic index, proliferating cell nuclear antigen-maximum proliferative index, in patients with colorectal cancer
71. A dose-finding study of lanreotide (a somatostatin analogue) in patients with colorectal carcinoma
72. Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients
73. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer
74. Treatment of hepatocellular carcinoma with octreotide: A randomized controlled study
75. Octreotide in advanced prostatic cancer relapsing under hormonal treatment
76. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas
77. Octreotide combined with goserelin in the therapy of advanced pancreatic cancer-results of a pilot study and review of the literature
78. Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues
79. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: In vitro and in vivo results
80. Expression of human somatostatin receptor subtype 3 in pancreatic cancer in vitro and in vivo
81. Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide
82. Somatostatin receptor: Scintigraphy and radionuclide therapy
83. Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype specific antibodies
84. Immunohistochemical localization of somatostatin receptors sst2A in human tumors
85. Response to treatment with yttrium-90-DOTA-lanreotide of a patient with metastatic gastrinoma
86. Expression of somatostatin receptors in peritumoral veins of human tumors
87. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples: Where are they really located?
88. Regression of liver metastases in patients with gastric-secreting tumor treated with SMS 201-995
89. Tumor regression of an ileacal carcinoid under the treatment with the somatostatin analogue SMS 201-995
90. Therapy for symptoms in the carcinoid syndrome
91. Occult retroperitoneal carcinoid tumor with flushing and solitary lung metastases
92. Regression of liver metastases of a carcinoid under treatment with the somatostatin analogue SMS
93. Resolution of musculoskeletal symptoms in the carcinoid syndrome after treatment with the somatostatin analog octreotide
94. Successful treatment of paraneoplastic hypocalcaemia of a carcinoid tumor with octreotide
95. Somatostatin analogues and carcinoid tumors
96. Plasma substance-P in neuroendocrine tumors and idiopathic flushing: The value of pentagastrin stimulation tests and the effects of somatostatin analog
97. Enteric hyperoxalosis due to treatment with a somatostatin analogue
98. Treatment of carcinoid syndrome with somatostatin analogue (SMS 201-995). Does the benefit justify the cost?
99. Somatostatin analogue treatment for malignant hypercalcaemia
100. Merkel cell tumor. Report of case and treatment with octreotide
101. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs
102. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide
103. Treatment of gastroenteropancreatic neuroendocrine tumors with octreotide LAR
104. Thyroid medullary carcinoma: Effects of s.c. sandostatin therapy in 18 cases
105. Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide
106. Octreotide therapy in advanced thyroid cancer
107. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon α-2b and octreotide
108. Endocrine effects of combined somatostatin analogue and bromocriptine therapy in woman with advanced breast cancer
109. The endocrine effects of bromocriptine and SMS201-995 in advanced breast cancer patients
110. Remission of metastatic breast cancer after combined somatostatin and anti-prolactin treatment
111. Biological and clinical evaluation of lanreotide, a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study of I.T.M.O. Group
112. Octreotide as first-line treatment for woman with metastatic breast cancer
113. Metastatic breast carcinoma with neuroendocrine differentiation-its combined therapy with tamoxifen and the somatostatin analog octreotide
114. Sandostatin, a long-acting somatostatin analogue, in the treatment advanced metastatic prostatic cancer
115. Octreotide and bromocriptine in patients with stage D2 prostate cancer who relapsed during treatment with flutamide and castration
116. The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma
117. Effect of octreotide on neuroenolase levels in patients with small-cell lung cancer
118. SMS 201-995 treatment and advanced intestinal cancer: A pilot study
119. Treatment of patients with metastatic pancreatic and gastrointestinal tumors with the somatostatin analogue Sandostatin: A phase II study including endocrine effects
120. The effect of long acting somatostatin analogue SMS 201-995 therapy on tumor kinetic measurements and serum tumor marker concentrations in primary rectal cancer
121. Somatostatin analogues and pancreatic acinar cell carcinoma: An alternative in symptomatic treatment?
122. Role of octreotide in the treatment of pancreatic cancer
123. Treatment of advanced pancreatic cancer with SMS 201-995
124. Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen
125. Regression of a distal bile duct carcinoma after treatment with octreotide for 6 months